

해외 바이오의약품 임상 현황 (2020.01.27 ~ 2020.02.02)

한국바이오의약품협회, 2020.2.3.
출처: ClinicalTrials.gov

○ 미국 62건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04207190	Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia	Recurrent Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia	Drug: Gemtuzumab Ozogamicin Other: Quality-of-Life Assessment Other: Questionnaire Administration Drug: Talazoparib Drug: Talazoparib Tosylate	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 1 Phase 2
NCT03532295	Epacadostat in Combination With Radiation Therapy and Avelumab in Patients With Recurrent Gliomas	Glioma Glioblastoma	Drug: Epacadostat Drug: Avelumab Drug: Bevacizumab Radiation: Radiation therapy Procedure: Peripheral blood draw	Washington University School of Medicine Incyte Corporation	Phase 1 Phase 2
NCT04222985	Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2	Genital Herpes	Biological: HSV 2 Formulation 1 Biological: HSV 2 Formulation 2 Biological: HSV 2 Formulation 3 Biological: HSV 2 Formulation 4 Biological: HSV 2 Formulation 5 Biological: HSV 2 Formulation 6 Biological: Sodium Chloride 0.9%	Sanofi Pasteur, a Sanofi Company Immune Design Sanofi	Phase 1 Phase 2
NCT04251416	A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma	Endometrial Carcinoma	Drug: Sacituzumab Govitecan	Alessandro Santin Immunomedics, Inc. Yale University	Phase 2
NCT04250051	Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia	Recurrent Acute Myeloid Leukemia Recurrent Myelodysplastic Syndrome Recurrent Myeloproliferative Neoplasm Refractory Acute Myeloid Leukemia Refractory Myelodysplastic Syndrome	Drug: Cytarabine Biological: Filgrastim Drug: Fludarabine Drug: Fludarabine Phosphate Drug: Ivosidenib	Northwestern University Agiros Pharmaceuticals National Cancer Institute (NCI)	Phase 1
NCT04248569	DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma	Fibrolamellar Hepatocellular Carcinoma (FLC)	Drug: DNAJB1-PRKACA peptide vaccine Drug: Nivolumab Drug: Ipilimumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bristol-Myers Squibb	Phase 1
NCT04248439	Gene Therapy for Fanconi Anemia, Complementation Group A	Fanconi Anemia Complementation Group A	Biological: RP-L102	Rocket Pharmaceuticals Inc.	Phase 2
NCT04244552	First-in-Human Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies	Breast Cancer Colorectal Cancer Ovarian Cancer Non Small Cell Lung Cancer Acral Lentiginous Melanoma	Biological: ATRC-101	Atreca, Inc.	Phase 1
NCT04236479	Mesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP)	Congenital Heart Disease (CHD)	Biological: BM-MSC	Catherine Bollard Children's Research Institute	Phase 1
NCT04231864	Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer	Epstein-Barr Virus Positive Metastatic Nasopharyngeal Carcinoma Recurrent Nasopharyngeal Carcinoma Stage III Nasopharyngeal Carcinoma Stage IV Nasopharyngeal Carcinoma Stage IVA Nasopharyngeal Carcinoma Stage IVB Nasopharyngeal Carcinoma	Biological: Durvalumab Drug: Epacadostat	Alain Algazi AstraZeneca Incyte Corporation University of California, San Francisco	Phase 2
NCT04231747	A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	Lymphoma Non-Hodgkin Aggressive Lymphoma Diffuse-large B-cell Lymphoma (DLBCL)	Biological: CC-97540	Juno Therapeutics, a Subsidiary of Celgene	Phase 1
NCT04220684	Off-the-shelf Third Party Expanded NK Cells in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome	Allogeneic Stem Cell Transplant Recipient Blasts 10 Percent or More of Bone Marrow Nucleated Cells Myelodysplastic Syndrome Recurrent Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia	Drug: Cytarabine Drug: Cytarabine Hydrochloride Drug: Decitabine Drug: Fludarabine Drug: Fludarabine Phosphate Biological: Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells	Sumithira Vasu National Cancer Institute (NCI) Ohio State University Comprehensive Cancer Center	Phase 1
NCT04209686	Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma	Advanced Gastric Adenocarcinoma	Drug: Paclitaxel Drug: Olaparib Drug: Pembrolizumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Merck Sharp & Dohme Corp.	Phase 2
NCT04205838	Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma	Diffuse Large B-Cell Lymphoma, Not Otherwise Specified High Grade B-Cell Lymphoma Progressive Disease Recurrent Diffuse Large B-Cell Lymphoma Recurrent High Grade B-Cell Lymphoma Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory High Grade B-Cell Lymphoma Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma	Biological: Anakinra Biological: Axicabtagene Ciloleuce Drug: Cyclophosphamide Drug: Fludarabine Drug: Fludarabine Phosphate	Jonsson Comprehensive Cancer Center National Cancer Institute (NCI)	Phase 2
NCT04205409	Nivolumab for Relapsed or Refractory Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies	Recurrent Chronic Lymphocytic Leukemia Recurrent Diffuse Large B-Cell Lymphoma Recurrent Follicular Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Grade 3a Follicular Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Non-Hodgkin Lymphoma Recurrent Plasma Cell Myeloma Refractory Chronic Lymphocytic Leukemia Refractory Diffuse Large B-Cell Lymphoma Refractory Follicular Lymphoma Refractory Marginal Zone Lymphoma Refractory Non-Hodgkin Lymphoma Refractory Plasma Cell Myeloma	Biological: Nivolumab	University of Washington National Cancer Institute (NCI) Bristol-Myers Squibb	Phase 2
NCT04205240	Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma	Recurrent Plasma Cell Myeloma	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Drug: Cyclophosphamide Biological: Daratumumab Drug: Fludarabine Drug: Melphalan Drug: Mycophenolate Mofetil Drug: Tacrolimus	Ohio State University Comprehensive Cancer Center National Cancer Institute (NCI)	Phase 2

해외 바이오의약품 임상 현황 (2020.01.27~2020.02.02)

한국바이오의약품협회, 2020.2.3.
출처: ClinicalTrials.gov

NCT04199767	SNIFF Multi-Device Study 2	Mild Cognitive Impairment Cognitive Impairment	Drug: 20 IU Humulin 羳 R U-100 (NDC: 0002-8215, Eli Lilly & Company) Drug: 40 IU Humulin 羳 R U-100 (NDC: 0002-8215, Eli Lilly & Company)	Wake Forest University Health Sciences	Phase 2
NCT04196010	G-CSF and Continuous Infusion Chemotherapy (CI-GCLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms	Myeloid Neoplasm Recurrent Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia	Drug: Cladribine Drug: Cytarabine Biological: Granulocyte Colony-Stimulating Factor Drug: Mitoxantrone	University of Washington National Cancer Institute (NCI)	Phase 1
NCT04195945	CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients	Acute Myeloid Leukemia Myeloid Neoplasm	Drug: Liposome-encapsulated Daunorubicin-Cytarabine Drug: Cladribine Drug: Cytarabine Biological: Granulocyte Colony-Stimulating Factor Drug: Mitoxantrone Other: Questionnaire Administration Other: Quality-of-Life Assessment	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI) Jazz Pharmaceuticals	Phase 2
NCT04195633	Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies	Acute Leukemia Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Adult Diffuse Large Cell Lymphoma Anaplastic Large Cell Lymphoma Burkitt Lymphoma Chronic Myelogenous Leukemia, BCR-ABL1 Positive Chronic Myelomonocytic Leukemia Hodgkin Lymphoma Lymphoblastic Lymphoma Lymphoplasmacytic Lymphoma Mantle Cell Lymphoma Mixed Phenotype Acute Leukemia Myelodysplastic Syndrome Prolymphocytic Leukemia Refractory Chronic Lymphocytic Leukemia Refractory Follicular Lymphoma Refractory Marginal Zone Lymphoma Refractory Small Lymphocytic Lymphoma	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Drug: Cyclophosphamide Drug: Cyclosporine Biological: Filgrastim Drug: Fludarabine Drug: Mycophenolate Mofetil Drug: Mycophenolate Sodium Radiation: Total-Body Irradiation Drug: Treosulfan	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI)	Phase 2
NCT04182490	LMN-101 in a Campylobacter Human Challenge Model	Campylobacter Infections	Biological: LMN-101	Lumen Bioscience, Inc. Naval Medical Research Center Phamaron CPC, Inc. University of Maryland, College Park	Phase 2
NCT04177810	Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer	Metastatic Pancreatic Cancer	Drug: Cemiplimab Drug: Plerixafor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Genzyme, a Sanofi Company American Association for Cancer Research	Phase 2
NCT04163419	Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis	Schwannomatosis Pain	Drug: Tanezumab Drug: Placebo	Massachusetts General Hospital Pfizer	Phase 2
NCT04160494	D2C7-IT With Atezolizumab for Recurrent Gliomas	Malignant Glioma	Drug: D2C7-IT (6920 ng/mL via convection-enhanced delivery) Drug: Atezolizumab (1200 mg every three weeks)	Darell D. Bigner, MD, PhD Istari Oncology, Inc. National Cancer Institute (NCI) Genentech, Inc. Duke University	Phase 1
NCT04150692	Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma	Multiple Myeloma	Biological: Daratumumab Procedure: Blood for research assessments Procedure: Bone marrow for research assessments	Washington University School of Medicine Janssen, LP	Phase 2
NCT04140526	Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC	Non Small Cell Lung Cancer Advanced Solid Tumor Metastatic Melanoma Metastatic Head and Neck Carcinoma Metastatic Renal Cell Carcinoma Metastatic Colorectal Cancer Sarcomas Metastatic Prostate Cancer	Drug: ONC-392 Drug: Pembrolizumab	Oncolmmune, Inc.	Phase 1
NCT04140162	Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma With Upfront Daratumumab-based Therapy	Multiple Myeloma	Drug: Daratumumab Drug: Lenalidomide Drug: Bortezomib Drug: Dexamethasone	University of Michigan Rogel Cancer Center Janssen Scientific Affairs, LLC	Phase 2
NCT04120246	Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer	Anatomic Stage IV Breast Cancer AJCC v8 ERBB2 Overexpression HER2 Positive Breast Carcinoma Metastatic Breast Carcinoma Prognostic Stage IV Breast Cancer AJCC v8 Refractory Breast Carcinoma	Drug: Alpha-tocopheryloxyacetic Acid Biological: Trastuzumab	University of Washington National Cancer Institute (NCI) Veana Therapeutics, Inc.	Phase 1
NCT04111445	Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors	Solid Tumor	Drug: ADG116	Adagene Inc	Phase 1
NCT04106362	Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma	Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 KRAS Protein Variant Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	Biological: Cetuximab Drug: Cisplatin Other: Quality-of-Life Assessment Other: Questionnaire Administration Radiation: Radiation Therapy	Jonsson Comprehensive Cancer Center National Cancer Institute (NCI)	Phase 2
NCT04103879	US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia	High Risk Hematological Malignancy Cord Blood Transplant	Biological: ECT-001-CB (UM171-Expanded Cord Blood Transplant)	ExCellThera inc. Fred Hutchinson Cancer Research Center	Phase 2
NCT04074746	Bispecific Antibody AFM13 Combined With NK Cells for Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas	Recurrent Anaplastic Large Cell Lymphoma Recurrent B-Cell Non-Hodgkin Lymphoma Recurrent Classic Hodgkin Lymphoma Recurrent Mycosis Fungoides Recurrent Peripheral T-Cell Lymphoma Refractory Anaplastic Large Cell Lymphoma Refractory B-Cell Non-Hodgkin Lymphoma Refractory Classic Hodgkin Lymphoma Refractory Mycosis Fungoides Refractory Peripheral T-Cell Lymphoma TNFRSF8 Positive	Biological: Anti-CD30/CD16A Monoclonal Antibody AFM13 Drug: Cyclophosphamide Drug: Fludarabine Drug: Fludarabine Phosphate Biological: Genetically Engineered Lymphocyte Therapy	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 1
NCT04070781	Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease	Steroid Refractory GVHD Graft Vs Host Disease	Drug: Itacitinib Drug: Tocilizumab	Columbia University Incyte Corporation	Phase 1
NCT04068753	Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer	Recurrent Cervix Cancer Progressive Cervix Cancer	Drug: Niraparib Drug: dostarlimab	University of Oklahoma Tesarro, Inc.	Phase 2

해외 바이오의약품 임상 현황 (2020.01.27 ~ 2020.02.02)

한국바이오의약품협회, 2020.2.3.
출처: ClinicalTrials.gov

NCT04058964	Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer	Metastatic Pancreatic Adenocarcinoma Stage IV Pancreatic Cancer AJCC v8	Biological: Pegylated Recombinant Human Hyaluronidase PH20 Biological: Pembrolizumab	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 2
NCT03993327	An Imaging Agent (I-124 M5A) in Detecting CEA-Positive Liver Metastases in Patients With Colorectal Cancer	Colorectal Carcinoma Metastatic in the Liver Metastatic Colorectal Carcinoma Stage IV Colorectal Cancer AJCC v8 Stage IVA Colorectal Cancer AJCC v8 Stage IVB Colorectal Cancer AJCC v8 Stage IVC Colorectal Cancer AJCC v8	Biological: Iodine I 124 Monoclonal Antibody M5A Procedure: Positron Emission Tomography	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1
NCT03982004	Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer	Metastatic Breast Cancer	Device: Epicutaneous cryoimmunotherapy Drug: Topical imiquimod Drug: Pembrolizumab Other: Dermatologic Quality of Life Index Other: Functional Assessment of Cancer Therapy Drug: Intra-lesional GM-CSF Device: Cry-AC Procedure: Cutaneous tumor biopsy Procedure: Peripheral blood draw for research	Washington University School of Medicine Merck Sharp & Dohme Corp.	Phase 1
NCT03969446	Pembrolizumab and Decitabine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory	Acute Myeloid Leukemia High Risk Myelodysplastic Syndrome Recurrent Acute Myeloid Leukemia Recurrent High Risk Myelodysplastic Syndrome Refractory Acute Myeloid Leukemia Refractory High Risk Myelodysplastic Syndrome Secondary Acute Myeloid Leukemia Therapy-Related Acute Myeloid Leukemia	Drug: Decitabine Biological: Pembrolizumab	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1
NCT03961971	Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM	Glioblastoma Multiforme	Drug: MBG453	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Novartis Pharmaceuticals	Phase 1
NCT03961815	Open-label Extension Study of Brazikumab in Crohn's Disease	Crohn's Disease	Drug: Brazikumab	Allergan	Phase 3
NCT03960541	CD24Fc Administration to Decrease LDL and Inflammation in HIV Patients (CALIBER)	HIV Infections Dyslipidemias	Drug: CD24Fc (human CD24 extracellular domain and human IgG1 Fc fusion protein) Drug: Saline Solution	Oncolimmune, Inc. University of Maryland, Baltimore National Heart, Lung, and Blood Institute (NHLBI)	Phase 2
NCT03832361	Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-Positive Endometrial Cancer	Endometrial Cancer	Drug: IMGN853	Alessandro Santin ImmunoGen, Inc. Yale University	Phase 2
NCT03679624	Daratumumab Plus Ibrutinib in Patients With Waldenström's Macroglobulinemia	Waldenstrom Macroglobulinemia Waldenstrom's Disease Waldenström; Hypergammaglobulinemia Waldenstrom's Macroglobulinemia Recurrent Waldenstrom's Macroglobulinemia of Lymph Nodes Waldenstrom's Macroglobulinaemia, Without Mention of Remission Waldenstrom's Macroglobulinemia Refractory	Drug: Ibrutinib Drug: Daratumumab	Weill Medical College of Cornell University Janssen Scientific Affairs, LLC Mayo Clinic	Phase 2
NCT03463239	Bioengineered Penile Tissue Constructs for Irreversibly Damaged Penile Corpora	Urologic Diseases Male Urogenital Diseases Penile Diseases Corpus Callosum Malformation Corpora Cavernosa; Inflammation Trauma Injury	Biological: Autologous tissue engineered corpora	Wake Forest University Health Sciences United States Department of Defense	Phase 1
NCT04232657	Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI	Spinal Cord Injury (=3 Years) Sublesional Bone Loss Secondary to SCI	Drug: Romosozumab Drug: Denosumab Drug: Placebo	VA Office of Research and Development Kessler Institute for Rehabilitation	Phase 2
NCT04167540	GDNF Gene Therapy for Parkinson's Disease	Parkinson's Disease	Biological: AAV2-GDNF	Brain Neurotherapy Bio, Inc.	Phase 1
NCT04154943	Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma	Cutaneous Squamous Cell Carcinoma	Drug: Cemiplimab	Regeneron Pharmaceuticals Sanofi	Phase 2
NCT04126070	Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors	Hormone Sensitive Prostate Cancer Prostate Adenocarcinoma Metastasis Prostate Adenocarcinoma	Drug: Androgen Deprivation Therapy Drug: Nivolumab Drug: Docetaxel	Xiao X. Wei Bristol-Myers Squibb Dana-Farber Cancer Institute	Phase 2
NCT04042506	SBRT as a Vaccination for Metastatic Melanoma	Metastatic Melanoma	Drug: Nivolumab 10 MG/ML Intravenous Solution [OPDIVO] Radiation: Stereotactic Body Radiation Therapy (SBRT)	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bristol-Myers Squibb	Phase 2
NCT04017130	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of TAK-169 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)	Relapsed and/or Refractory Multiple Myeloma	Drug: TAK-169	Millennium Pharmaceuticals, Inc. Takeda	Phase 1
NCT03956056	Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy	Pancreas Cancer Pancreatic Cancer Cancer of the Pancreas	Biological: Neoantigen Peptide Vaccine Drug: Poly ICLC Procedure: Blood for immune monitoring	Washington University School of Medicine National Institutes of Health (NIH) National Cancer Institute (NCI)	Phase 1
NCT04191421	Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer	Metastatic Pancreatic Adenocarcinoma Stage IV Pancreatic Cancer AJCC v8	Biological: Siltuximab Biological: Spartalizumab	Emory University Novartis EUSA Pharma	Phase 1 Phase 2
NCT04098250	Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH	Post-Traumatic Headache	Drug: Erenumab Other: Placebo	Mayo Clinic University of Arizona Translational Genomics Research Institute Arizona State University Phoenix VA Health Care System United States Department of Defense Amgen	Phase 2
NCT04230109	Sacituzumab Govitecan In TNBC	Invasive Breast Cancer Triple Negative Breast Cancer ER-Negative Breast Cancer PR-Negative Breast Cancer HER2-negative Breast Cancer	Drug: Sacituzumab Govitecan	Aditya Bardia Immunomedics, Inc. Massachusetts General Hospital	Phase 2
NCT04084951	Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors	Adult Solid Tumor	Biological: SQZ-PBMC-HPV Drug: Atezolizumab	SQZ Biotechnologies	Phase 1

해외 바이오의약품 임상 현황 (2020.01.27 ~ 2020.02.02)

한국바이오의약품협회, 2020.2.3.
출처: ClinicalTrials.gov

NCT04219254	A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	Solid Tumor, Adult	Biological: BI-1206	BioInvent International AB	Phase 1 Phase 2
NCT04225260	Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines	Glabellar Lines Lateral Canthal Lines	Biological: botulinum toxin neuromodulator	Q-Med AB	Phase 3
NCT04176120	Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)	Diabetic Foot Infection Non-healing Wound Non-healing Diabetic Foot Ulcer	Biological: TTAX01 Other: Standard Care	Tissue Tech Inc.	Phase 3
NCT04206605	Efficacy and Safety of Lanadelumab for Prevention Against Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) and Acquired Angioedema (AAE) Due to C1-INH Deficiency	Angioedema	Drug: Lanadelumab Other: Placebo	Shire	Phase 3
NCT04145193	Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC	Microsatellite-stable Colorectal Cancer	Drug: Standard of Care - mFOLFOX6 Drug: E1 - mFOLFOX and durvalumab Drug: E2 - mFOLFOX6, durvalumab and oleclumab Drug: E3 - mFOLFOX6, durvalumab and monalizumab	MedImmune LLC	Phase 2
NCT04158648	A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors	Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor Hemophilia A	Drug: Emicizumab	Hoffmann-La Roche	Phase 3
NCT03911505	ZIP Study - A Study to Evaluate the PK, Safety, Efficacy, and PD With ATB200/AT2221 in LOPD Subjects Aged 12 to <18	Pompe Disease (Late-onset)	Biological: ATB200 Drug: AT2221	Amicus Therapeutics	Phase 3

○ 영국 3건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04075331	Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial	COPD Eosinophilia	Drug: Mepolizumab Drug: Placebo	University of Leicester Leicester Clinical Trials Unit GlaxoSmithKline	Phase 2 Phase 3
NCT04241601	Low-dose Interleukin-2 for the Reduction of Vascular Inflammation in Acute Coronary Syndromes - IVORY	Acute Coronary Syndromes	Drug: Interleukin-2 [IL-2] Other: Placebo Dextrose 5% solution	Cambridge University Hospitals NHS Foundation Trust	Phase 2
NCT04158648	A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors	Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor Hemophilia A	Drug: Emicizumab	Hoffmann-La Roche	Phase 3

○ 프랑스 5건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04166656	Research Trial Assessing the Immunogenicity and Safety of Three Meningococcal B Vaccine Strategies Among Patients With Asplenia.	Splenectomy	Biological: Trumenba Biological: Bexsero	Assistance Publique - H ^ô pitaux de Paris EUCLID Clinical Trial Platform Recherche Clinique Paris Descartes Necker Cochin Sainte Anne CIC 1417 Cochin Pasteur Innovative clinical research in vaccinologie (I-REIVAC) Institut Pasteur	Phase 3
NCT03892785	MEthotrexate Versus TOcilizumab for Treatment of Giant Cell Arteritis: a Multicenter, Randomized, Controlled Trial	Giant Cell Arteritis	Drug: Prednisone treatment Drug: Tocilizumab treatment Drug: Methotrexate treatment Other: Questionnaires Biological: Blood samples	Centre Hospitalier Universitaire Dijon	Phase 3
NCT04216953	MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma	Sarcoma,Soft Tissue	Drug: Cobimetinib Drug: Atezolizumab	Centre Leon Berard	Phase 1 Phase 2
NCT04145193	Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC	Microsatellite-stable Colorectal Cancer	Drug: Standard of Care - mFOLFOX6 Drug: E1 - mFOLFOX and durvalumab Drug: E2 - mFOLFOX6, durvalumab and oleclumab Drug: E3 - mFOLFOX6, durvalumab and monalizumab	MedImmune LLC	Phase 2
NCT04158648	A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors	Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor Hemophilia A	Drug: Emicizumab	Hoffmann-La Roche	Phase 3

○ 독일 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04228354	A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide	Healthy Volunteers Overweight Obesity	Drug: Semaglutide	Novo Nordisk A/S	Phase 1
NCT04158648	A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors	Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor Hemophilia A	Drug: Emicizumab	Hoffmann-La Roche	Phase 3

해외 바이오의약품 임상 현황 (2020.01.27 ~ 2020.02.02)

한국바이오의약품협회, 2020.2.3.
출처: ClinicalTrials.gov

○ 중국 7건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04247945	Co-transplantation of MSC in the Setting of Allo-HSCT	Allogeneic Hematopoietic Stem Cell Transplantation	Biological: Cotransplant with MSCs	Fujian Medical University	Phase 2 Phase 3
NCT04233294	Chidamide in Combination With Camrelizumab Alone or Plus Decitabine in Relapsed/Refractory Classical Hodgkin Lymphoma	Hodgkin Lymphoma	Drug: Chidamide Drug: Camrelizumab Drug: Decitabine	Chinese PLA General Hospital	Phase 2
NCT04215731	Neoadjuvant mFOLFOXIRI Plus Bevacizumab With Selective Radiotherapy in Patients With High-Risk Locally Advanced Rectal Cancer	Rectal Cancer	Drug: Neoadjuvant chemotherapy with mFOLFOXIRI plus bevacizumab Procedure: Restaging Radiation: Concomitant Chemoradiotherapy Procedure: Surgery Radiation: Selective chemoradiotherapy Drug: Induction chemotherapy with FOLFOX	Yanhong Deng Sun Yat-sen University	Phase 3
NCT04215471	NeoAdjuvant Therapy With Immunoreagent (SHR-1316) for Resectable Oesophageal Squamous Cell carcinoma	Oesophageal Squamous Cell Carcinoma	Drug: PD-L1 Antibody SHR-1316	Shanghai Zhongshan Hospital	Phase 2
NCT04211168	Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers	Advanced Biliary Tract Cancer	Drug: Toripalimab plus Lenvatinib	Peking Union Medical College Hospital Shanghai Junshi Biosciences Co., LTD	Phase 2
NCT04211012	A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Carcinoma	Urothelial Carcinoma	Drug: Toripalimab plus Nab-Paclitaxel +/- cisplatin	Jun Guo Beijing Cancer Hospital	Phase 2
NCT04024462	A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer	HER2-positive Early Breast Cancer	Drug: Pertuzumab IV Drug: Trastuzumab IV Drug: FDC of Pertuzumab and Trastuzumab SC Drug: Doxorubicin Drug: Cyclophosphamide Drug: Docetaxel Procedure: Surgery Radiation: Post-Operative Radiotherapy Drug: Hormone Therapy	Hoffmann-La Roche	Phase 3